11-Ketotestosterone is the predominant active androgen in prostate cancer patients after castration

BACKGROUND: Continued androgen receptor (AR) signaling constitutes a key target for treatment in metastatic castration-resistant prostate cancer (CRPC). Studies have identified 11-ketotestosterone (11KT) as a potent AR agonist, but it is unknown if 11KT is present at physiologically relevant concent...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:JCI Insight
Päätekijät: Snaterse, Gido, van Dessel, Lisanne F., van Riet, Job, Taylor, Angela E., van der Vlugt-Daane, Michelle, Hamberg, Paul, de Wit, Ronald, Visser, Jenny A., Arlt, Wiebke, Lolkema, Martijn P., Hofland, Johannes
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society for Clinical Investigation 2021
Aiheet:
Clinical Medicine
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8262344/
https://ncbi.nlm.nih.gov/pubmed/33974560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.148507
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia